Remifentanil Target Controlled Infusion Versus Standard of Care for Conscious Sedation During EBUS-TBNA
- Conditions
- Lung; NodeLung CancerSedation ComplicationEndoscopy
- Interventions
- Registration Number
- NCT06033729
- Lead Sponsor
- Scarlata, Simone, M.D.
- Brief Summary
Background: endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure for diagnosing and staging mediastinal lymph node lesions in lung cancer. Adequate sedation is crucial for patient comfort and diagnostic accuracy. Different sedation modalities, including moderate sedation/conscious sedation, deep sedation, and general anesthesia, are utilized. This study aims to evaluate patient comfort and satisfaction levels of healthcare providers (bronchoscopists and anesthesiologists) when administering remifentanil through Target Controlled Infusion (TCI) for conscious sedation during EBUS-TBNA. A prospective randomized study design compares this approach to the standard sedation protocol involving midazolam, fentanyl, and/or propofol.
Methods: this study will enroll 30 eligible patients randomly divided into two groups. Group 1, "REMIFENTANIL TCI", underwent EBUS-TBNA under conscious sedation with remifentanil TCI infusion targeting a concentration of 3-6 ng/ml. Group 2, "STANDARD", received conscious sedation with a combination of midazolam, fentanyl, and/or propofol administered in boluses based on clinical requirements. Complications, safety, and satisfaction levels of the operator, anesthesiologist, and patients will be evaluated.
- Detailed Description
BACKGROUND Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure that has gained major relevance in diagnosis lung cancer and staging of mediastinal lymph nodes (LN). Adequate sedation is an important part of the procedure since it improves patient's comfort and tolerance potentially positively affecting the diagnostic yield. It is also considered a standard of care for patients undergoing fiberoptic bronchoscopy unless specifically contraindicated.
The choice of the different level of sedation (from conscious to moderate to deep sedation) has always been challenging and, to date, no standardized practice exists. Deep sedation may be preferred in those cases where additional procedures such as placement of endobronchial stents, are required, or in order to make the procedure more suitable by limiting the patients motion. In remaining cases, conscious sedation allows to complain with the clinical demand without affecting respiratory and cardiovascular function, decreasing the cough reflex and maintaining sufficient swallowing capacity.
Not appropriate sedation can have serious complications, including respiratory depression or even arrest, hypoxia and/or hypercapnia, and cardiovascular and neurological side effects.
Commonly used drugs for sedation include propofol and a combination of benzodiazepines and opioids. However, achieving the ideal level of sedation can be challenging, since it may occasionally lead to over sedation, with detrimental effects. These risks are even greater if the patients present with lung disease, obesity, or heart disease. Conversely, under sedation can result in discomfort for the patient and challenging procedure it for the healthcare provider. Furthermore, benzodiazepines and medium-long-acting opioids continue their effect even after the procedure is finished, thus lasting the negative effects of these drugs over the time of the procedure.
In a recent case series, Scarlata and colleagues have provided a preliminary evidence of a TCI remifentanil protocol safety and effectiveness, providing an ideal and performant condition for bronchoscopists and a satisfactory comfort for patients.
Using a TCI continuous infusion protocol of Remifentanil can exploit the sedative, analgesic and antitussive capabilities of this short-acting opioid, achieving a level of conscious sedation that ensures an adequate level of comfort for the patient while at the same time decreases the incidence of side effects typical of deep sedation. The patient remains contactable and can respond and execute commands, such as breathing, swallowing, etc.
TCI is a method of continuous drug administration where the infusion of the drug is remotely controlled. There are different administration algorithms and there is the possibility to titrate the target concentration both at the effect site (CNS) and in the plasma.
There are numerous studies confirming the efficacy of remifentanil administered by TCI during intubation with an awake patient, and the advantages of the latter compared to other techniques, such as propofol infusion. One study determined the efficacy of infused remifentanil and propofol for bronchial endoscopy procedures, but did not use the TCI technique for infusion. There are no clinical studies assessing endoscopic transbronchial needle biopsy procedures with remifentanil infusion in TCI mode.
The aim of this study is therefore to conduct a prospective, randomized, controlled trial to evaluate the administration of remifentanil in TCI for conscious sedation during EBUS-TBNA procedures, the degree of patient and operator satisfaction and the relative advantages and disadvantages versus the of standard sedation protocol with midazolam and/or fentanyl and/or propofol.
METHODS This is a single center, randomized, investigator initiated clinical trial of 30 patients undergoing EBUS-TBNA for mediastinal staging of lung cancer. Patients were randomly assigned to one of two groups: Group 1 "REMIFENTANIL TCI" (Experimental Group): the patients performed the EBUS-TBNA procedure under conscious sedation with infusion of Remifentanil TCI with a target between 3 and 6 ng/ml; Group 2 "STANDARD" (Control Group): the patients performed the EBUS-TBNA procedure in conscious sedation with the association of midazolam and/or fentanyl and/or propofol in refracted boluses based on clinical needs (agitation, unsatisfactory level of sedation or not collaborative patient) and according to the anesthesiologist's clinical judgement.
After obtaining a signed informed consent the patient was randomly allocated 1:1 to the group "REMIFENTANIL TCI" or "STANDARD". A research randomizer software was used for randomization (iRANDOMIZER-SHMOOPI LLC-version 2.5). Both the bronchoscopist and the research assistant administrating the questionnaires were blinded to the assigned group. It was not possible to blind anesthesiologists involved in the patient's care.
The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
Study treatment The ASA scale, the Mallampati score, the presence of OSAS were recorded prior of the procedure. Also, data about the underlying oncological disease, whether chemotherapy and/or radiotherapy was performed, and the indication for the EBUS-TBNA test (diagnostic, staging, re-staging, or both diagnostic and staging at the same moment) were collected.
The patient candidate for the endoscopic procedure underwent continuous monitoring of vital signs. ECG with precordial leads, continuous finger pulse oximetry, and noninvasive intermittent blood pressure measurements were monitored. Each patient was preoxygenated for about 5 minutes by administering O2 with nasal goggles at 3L/min or higher, if required.
Lidocaine was topically nebulized at the level of the mucous membranes of the oropharynx. Oxybuprocaine 4mg/ml was also nebulized at the level of the vocal cords via the eco-endoscope before passing the glottic plane in all patients.
Remifentanil group conscious sedation protocol (intra venous remifentanil in TCI). Drug administration begun 5 minutes before the procedure. The achievement of the ideal target occurs starting from an initial target at the effect site of 1 ng/ml and gradually increasing the desired target on the pump by 0.5 ng/ml at a time, until reaching a target between 3 and 6 ng/ml and an adequate level of sedation (Ramsey Score between 2-3).
Desired target was achieved by automatic infusion pumps (Infusomat® Space® Large Volume Pump, Braun medical inc) If, despite the maximum target, a satisfactory level of sedation was not reached, repeated boluses of propofol were given as clinically needed and the case considered as protocol failure.
Patients in the STANDARD Group performed the EBUS-TBNA with bolus administration of midazolam and/or fentanyl and/or propofol. Shortly before the start of the procedure they received 1-2 mg bolus midazolam and/or 50-100 range bolus fentanyl until they reach the level of sedation (Ramsey Score 2-3). In addition, repeated boluses of propofol could have been given according to clinical needs (state of agitation of the patient, requests from the operator due to difficulties in carrying out the procedure).
Data were collected about the procedure performed, any changes in vital signs that occurred during the procedure and the depth of sedation.
Anesthesiologist, bronchoscopist and patient's satisfaction tools At the end of the procedure, the patient was given a satisfaction questionnaire to evaluate the degree of satisfaction. The 0-5 Likert numerical scale was used to evaluate the symptoms onset of cough (0 none-5 very much), sore throat (0-5), chest pain (0-5), shortness of breath (0 eupnoea- 5 worsening dyspnea), presence of memories (0 none - 5 vivid memories), and perioperative comfort (0 none - 5 excellent). The operator who performed the procedure and the sedation were also subjected to a satisfaction questionnaire which assessed the overall satisfaction (1 much worse than usual - 5 much better than usual).
Statistical Analysis The analysis was performed on an intention to treat basis, regardless of actual compliance with the intended intervention.
A two-tailed p value equal or less than 0.05 was considered as statistically significant. All tests, except for the primary outcome, were considered merely exploratory. When individual items were missing from a scale, the percent of missing values and, if more than 10% was calculated, the scale score was considered missing and therefore made unavailable for analysis. All the analyses were conducted using STATA (StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC.).
Outcome analysis Primary and secondary endpoints will be compared between the two groups of treatment by means of Student's t-test (or the Mann-Whitney U test, if necessary) for continuous quantitative variables and by means of the χ2 test (or Fisher's exact test ) for qualitative variables.
Sample size determination Our previously published case series showed that the overall satisfaction rate for both the patient and the bronchoscopist were very high in the remifentanil TCI group (mean Likert score above 4/5 against a mean value ranging from 2 to 3 in the standard group as available in the literature). Enrolling 30 patients (fifteen for each group) would have provided with 80% power at an alpha level of 0.05.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
- patients aged 18-80 years,
- clinical fit to undergo the planned procedure, according to the American Society of Anesthesiologists physical status classification.
- current chronic opioid treatment,
- substance abuse or drug use;
- pregnancy,
- history of allergy to related medications;
- severe coagulation dysfunction;
- severe hepatic
- renal dysfunction;
- history of abnormal recovery from anesthesia;
- acute respiratory failure;
- inability or unwillingness to provide informed consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 2 "STANDARD" (Control Group) Midazolam injection the patients performed the EBUS-TBNA procedure in conscious sedation with the association of midazolam and/or fentanyl and/or propofol in refracted boluses based on clinical needs (agitation, unsatisfactory level of sedation or not collaborative patient) and according to the anesthesiologist's clinical judgement. Group 1 "REMIFENTANIL TCI" (Experimental Group) Remifentanil TCI the patients performed the EBUS-TBNA procedure under conscious sedation with infusion of Remifentanil TCI with a target between 3 and 6 ng/ml; Group 2 "STANDARD" (Control Group) Fentanyl the patients performed the EBUS-TBNA procedure in conscious sedation with the association of midazolam and/or fentanyl and/or propofol in refracted boluses based on clinical needs (agitation, unsatisfactory level of sedation or not collaborative patient) and according to the anesthesiologist's clinical judgement. Group 2 "STANDARD" (Control Group) Propofol the patients performed the EBUS-TBNA procedure in conscious sedation with the association of midazolam and/or fentanyl and/or propofol in refracted boluses based on clinical needs (agitation, unsatisfactory level of sedation or not collaborative patient) and according to the anesthesiologist's clinical judgement.
- Primary Outcome Measures
Name Time Method Patient, bronchoscopist and anesthesiologist's comfort and satisfaction to the procedure. At patient's dismission from bronchoscopy suit the patient was given a satisfaction questionnaire to evaluate the degree of satisfaction. The 0-5 Likert numerical scale was used to evaluate the symptoms onset of cough (0 none-5 very much), sore throat (0-5), chest pain (0-5), shortness of breath (0 eupnoea- 5 worsening dyspnea), presence of memories (0 none - 5 vivid memories), and perioperative comfort (0 none - 5 excellent). The operator who performed the procedure and the sedation were also subjected to a satisfaction questionnaire which assessed the overall satisfaction (1 much worse than usual - 5 much better than usual).
- Secondary Outcome Measures
Name Time Method Desaturation Up to an hour from the end of the procedure Desaturation episodes
Hypotension Up to an hour from the end of the procedure Episodes of hypotension (SBP \<90 mmHg)
Over sedation During the procedure Episodes of over-sedation (Ramsey score \> 3)
Airway support Up to an hour from the and of the procedure Need for airway support
Sampled lymph nodes During the procedure Number of lymph nodes sampled during the procedure.
Sampled lesions During the procedure Number of masses sampled during the procedure.
Cough Up to two hours from the end of the procedure Excessive cough (Unconfortable, unconstrained cough affecting patient's and operator comfort)
propofol boluses administered During the procedure Number and dosage of any propofol boluses administered (both in the experimental group and in the control group)
Procedure time During the procedure Total duration of the procedure (in minutes)
Level of sedation During the procedure Level of sedation achieved (Ramsey score)
Bradycardia Up to an hour from the end of the procedure Episodes of Bradycardia (HR\<60)
Bradypnea or respiratory arrest Up to an hour from the end of the procedure Episodes of bradypnea (RR\<10)
Number of biopsies per limph node During the procedure Number of biopsies per single lymph node needed to obtain a confident sample size according to a visual on-site evaluation.
Number of biopsies per mass During the procedure Number of biopsies per single mass needed to obtain a confident sample size according to a visual on-site evaluation
Trial Locations
- Locations (1)
Università Campus Bio Medico
🇮🇹Roma, Italy